SCHEDULE: Rubric Capital and David Rosen Disclose Nearly 9.5% Stake in Integra Lifesciences
Beneficial Ownership Report (Schedule 13G Amendment)
Rubric Capital Management LP and David Rosen have disclosed a 9.46% beneficial ownership stake in Integra Lifesciences Holdings Corporation, holding over 7.3 million shares.
Summary
- Rubric Capital Management LP and David Rosen collectively reported beneficial ownership of 7,353,934 shares of Integra Lifesciences Holdings Corporation common stock.
- This ownership represents 9.46% of the Issuer's outstanding common stock.
- The percentage is calculated based on 77,712,274 shares of common stock outstanding as of May 2, 2025, as reported in Integra Lifesciences' Quarterly Report on Form 10-Q filed May 5, 2025.
- The shares are held with shared voting power and shared dispositive power by both Rubric Capital Management LP and David Rosen.
- Rubric Capital Master Fund LP, a Rubric Fund, has the right to receive or direct dividends and proceeds from the sale of more than 5% of the Common Stock.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This filing indicates a significant institutional investment in Integra Lifesciences, a company operating in the medical technology and healthcare sector. Such a substantial stake by an investment adviser like Rubric Capital Management LP can signal confidence in the company's long-term prospects or a strategic interest in its future direction within the broader healthcare industry.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- The disclosure of a significant ownership stake by Rubric Capital Management LP and David Rosen may be viewed positively by existing shareholders, potentially signaling institutional confidence in Integra Lifesciences.
- The statement that the shares are not held for the purpose of changing or influencing control, other than activities solely in connection with a nomination under Rule 14a-11, suggests a passive investment approach, which may reassure current management and employees.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-05-02 | Date as of which 77,712,274 shares of Common Stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q. |
| 2025-05-05 | Date the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, was filed with the SEC. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-07-09 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Integra Lifesciences Holdings Corporation, Rubric Capital Management LP, David Rosen, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Institutional Ownership, Healthcare, Medical Devices
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.